The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Metabolomic processes have been identified as being strongly linked to the development of Alzheimer's disease (AD). Thus, lipid metabolites appear to be highly useful as diagnostic substrates for the diagnosis of AD and mild cognitive impairment (MCI) in plasma. Methods: We analyzed plasma samples from controls (n = 35), MCI (n = 33), and AD patients (n = 43) using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences), which included quantitative analysis of 40 acylcarnitines, 21 amino acids, 19 biogenic amines, 15 sphingolipids, 90 glycerophospholipids, and sum of hexoses. Results: We found that individual lipid metabolites can differentiate controls from MCI and AD with relevant significance. However, the ratio between PC aa C34:4 and lysoPC a C18:2 differentiates controls from MCI (P = .0000007) and from AD (P = .0000009) with greater significance. Conclusions: The results provide evidence that the ratio of these two lipid metabolites is useful for diagnosing MCI and AD with an accuracy of 82%–85%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A survey of cross-validation procedures for model selection
Arlot, S., & Celisse, A. (2010) · Statistics Surveys · doi:10.1214/09-ss054 · Cited by 3,522 · cited 1×
“Bias-corrected estimates of sensitivity and specificity were obtained using leave-one-out cross-validation [21].”
MethodClassification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“[8] claimed to diagnose AD from plasma using a panel of 18 biomarkers.”
MethodBlood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Identifying and validating biomarkers for Alzheimer's disease
Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484
Self-citationTau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · cited 1×
“dependent of b-amyloid [2] but recent evidence indicates that both proteins interact [3].”
BackgroundHuman serum metabolic profiles are age dependent
Yu, Z., Zhai, G., Singmann, P., He, Y., Xu, T., Prehn, C., Römisch‐Margl, W., Lattka, E., Gieger, C., Soranzo, N., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00865.x · Cited by 340
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · cited 1×
“There is more and more evidence to show that a single biomarker cannot yield enough sensitivity and specificity to diagnose AD [6,7].”
BackgroundEvaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135 · cited 1×
“However, several groups including ours failed to reproduce this finding [9,10].”
Background
Cited by
An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases
Law, S.-H., Chan, M.-L., Marathe, G. K., Parveen, F., Chen, C.-H., & Ke, L.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051149 · Cited by 817
The mechanisms of lysophosphatidylcholine in the development of diseases
Liu, P., Zhu, W., Chen, C., Yan, B., Zhu, L., Chen, X., & Peng, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117443 · Cited by 579
Metabolic network failures in Alzheimer's disease: A biochemical road map
Toledo, J. B., Arnold, M., Kastenmüller, G., Chang, R., Baillie, R. A., Han, X., Thambisetty, M., Tenenbaum, J. D., Suhre, K., Thompson, J. W., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.020 · Cited by 468
Self-citationNeuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
Alzheimer’s Disease: An Update and Insights Into Pathophysiology
Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W., Kamal, H., Ibrahim, N. H., Khoo, C. S., & Kumar, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.742408 · Cited by 279
Metadata
- Authors
- Klavins, K., Koal, T., Dallmann, G., Marksteiner, J., Kemmler, G., & Humpel, C.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2015-06-27
- Volume
- 1
- Issue
- 3
- Pages
- 295-302
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W1780739842
- Cited by
- 110
- References
- 9
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. https://app.cochat.ai/papers/10.1016/j.dadm.2015.05.003
- The paper
- Klavins, K., Koal, T., Dallmann, G., Marksteiner, J., Kemmler, G., & Humpel, C. (2015). The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1016/j.dadm.2015.05.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.